S.Korea's pharma shrs jump on plans to revise supervisory standards on accounting rules

Medipost Co

31/08/2018 02:16

** South Korea's pharmaceutical and biotechnology firms rise
on expectations of stronger research and development (R&D)
competitiveness due to eased supervisory standards on accounting
rules
    ** Vice chairman of the country's top financial regulator
said on Thursday that it will revise supervisory standards on
accounting rules for R&D spending - Yonhap News Agency
 urn:newsml:reuters.com:*:nNRA6s778c
    ** The current supervisory rule does not specify when a
pharmaceutical or biotechnology company should treat its
research and development spending as an asset in its accounting
book, according to the regulator
    ** Shares of Samsung Biologics Co Ltd  207940.KS  climb as
much as 5.2 pct, while Medipost Co Ltd  078160.KQ  and Hanmi
Pharm Co Ltd  128940.KS  gain 8.5 pct and 1.9 pct, respectively
    ** The sub-index for medical supplies  .KS32  edge up 1.8
pct
    ** The broader market  .KS11  down 0.2 pct as of 0111 GMT

 ((Reuters Messaging: joori.roh.thomsonreuters.com@reuters.net))